Drug Profile

Anti-CD3 anti-CD20 bispecific antibody - Protheragen

Alternative Names: Anti-CD3/CD20 bispecific antibody; CD3xCD20 bsAb

Latest Information Update: 28 Jan 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Protheragen
Class Antineoplastics; Bispecific antibodies; Immunotherapies
Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

28 Jan 2024 No recent reports of development identified for preclinical development in Lymphoma in USA (Parenteral)
17 Dec 2019 Anti-CD3 anti-CD20 bispecific antibody - Protheragen is available for licensing as of 17 Dec 2019. [https://www.protheragen.com
17 Dec 2019 Protheragen has patents pending for anti-CD3 anti-CD20 bispecific antibody (Protheragen pipeline, December 2019)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com